In the public interest.
The OneChoice® Report breaks down complicated molecular diagnostic results into easy to read interpretations and well-researched recommendations that maximize physician efficiency. Every report contains our unique ArkScore™ to help prescribers make informed decisions when choosing the right antibiotic.
Research shows that recommendations by a specialist physician are adhered to as opposed to those by pharmacists or nurses, so our recommendations are written for doctors and are constantly reviewed by members of our Infectious Disease Team.
The OneChoice® decision engine combines machine-learning artificial intelligence with decades of deep infectious disease expertise to guide physicians to a singular treatment regimen that targets the most relevant infection, with the lowest risk to the patient.
The patent-pending ArkScore™ System helps prescribers make better-informed decisions. It combines our expertise in antimicrobial stewardship with complex algorithms and a deep understanding of infectious disease.
Through a simple numerical scale, the ArkScore™ communicates the level of antimicrobial resistance expressed in the organisms found, and provides the most effective treatment, with the least risk for adverse events, reducing the unnecessary use of broad-spectrum antibiotics.
Antimicrobial Resistance ArkScore™
measures levels of antimicrobial resistance expressed in the detected organisms. Lower scores denote low resistance, in which case the antibiotic of choice can be given with less concern about adverse outcomes. A higher score indicates higher levels of resistance, limiting the antibiotic options available, increasing risk to the patient.
Adverse Reaction ArkScore™
provides important information to the prescriber about the specific drug being recommended. The lower the score, the safer, more effective and less risk-associated with use of that drug. The lower the score the more adverse events and risks to the patient associated with the antibiotic.
Infection Complexity ArkScore™
provides a more complete picture to prescribers and caregivers of the level of difficulty presented by the detected organisms and resistance genes, when choosing a treatment plan.
ALLIED LUCKY LIMITED GOLDTONE HOLDING LIMITED JOBXPRESS MANAGEMENT SERVICES INC Lokseva International Inc. Kingsing Trading Limited Sinocable International Limited Sinowealth Resource Limited HONGKONG BOCHENG PHARMACY GROUP LIMITED GLORY ZHANGJIAGANG LIMITED ROTHWELL INVESTMENTS ALLIANCE LIMITED ELSHAM FINANCE CORP. MONSELL HOLDINGS LTD. REGARTH INTERNATIONAL LIMITED ARKSTONE HOLDINGS LIMITED Global Absolute Group Holdings Ltd LABERTON FINANCE LTD NELSON FOREST LTD DELKSHIRE INTERNATIONAL LTD. SHEFER CAPITAL LTD SIB GLOBAL INC. VDC Holdings Ltd. FORDTEX GLOBAL INVESTMENT LTD. RELTON FINANCE LTD. ValueMas Inc Delta First Property Limited Interfex S.A. HASSELBECK COMMODITES CORP. MMG CONSULTING SERVICES INC. Bili Management Corporation Tongbao Finance Services Group Inc. STERN C'S LIMITED Hybrid Kinetic Automotive Holdings Limited Abundant Wish Group Limited PARASCON LIMITED Breeze Sails Overseas Ltd GLOBAL WATER DESIGN CO. LTD. KIMOUCHI LTD. MBF Trading Corp HUAMAO INTERNATIONAL LTD Dual Luxury Group Ltd EO GROUP MANAGEMENT HOLDINGS LTD. 3205 27TH AUGUST, 2010